Finasteride is a specific type II 5α-reductase competitive inhibitor that inhibits the conversion of peripheral testosterone to dihydrotestosterone and reduces dihydrotestosterone levels in blood and prostate, skin and other tissues. The growth and development of the prostate gland and benign hyperplasia depend on dihydrotestosterone. Finasteride inhibits prostate hyperplasia and improves the clinical symptoms associated with BPH by reducing dihydrotestosterone levels in the blood and prostate tissue. Indications: 1. Treatment of benign prostatic hyperplasia (BPH) by reducing the size of the enlarged prostate, improving urinary flow and improving symptoms associated with prostatic hyperplasia; 2. Prevention of urinary events: Reduces the risk of acute urinary retention; reduces the risk of transurethral resection of the prostate (TURP). The clinical use of finasteride for the treatment of prostatic hyperplasia is not fast-acting and requires long-term medication for months or even years, probably due to the slow progression of prostatic hyperplasia itself. Adverse effects: Finasteride is well tolerated by patients. The main clinical side effects are impaired sexual function, breast discomfort and skin rash. Contraindications: 1. Not for use in women and children. 2. Contraindicated in the following conditions: Hypersensitivity to any of the components of this product. Pregnancy – Pregnant and potentially pregnant women. Precautions: 1. General precautions: Patients with large amounts of residual urine and/or severely reduced urine flow should be closely monitored for obstructive uropathy. 2. Drug/lab test interactions: In most patients, PSA decreases rapidly within the first month of treatment, followed by stabilization of PSA levels at a new baseline. The post-treatment baseline value is approximately half of the pre-treatment baseline value. Therefore, patients treated with finasteride for six months or longer should have their PSA values doubled when compared to normal PSA values in untreated men. 3. Pregnancy: Contraindicated in women who are pregnant or likely to conceive. Because type II 5a-reductase inhibitors, including finasteride, have the effect of inhibiting the conversion of testosterone to dihydrotestosterone, they can cause male fetal external genital abnormalities when taken by pregnant women. 4. Exposure to Finasteride – Risk to the male fetus: Because of the potential for absorption of finasteride and subsequent risk to the male fetus, women should not touch fragments and lobes of Paulette when they are pregnant or may become pregnant.